XERIS BIOPHARMA HOLDINGS, INC. (XERS) Total liabilities 2020–2025
XERIS BIOPHARMA HOLDINGS, INC. (XERS) total liabilities at each fiscal year-end, per SEC filings.
$369.8MFY2025 · since FY2020: $125.4M → $369.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $369.8M | +4.9% |
| FY2024 | $352.7M | +7.1% |
| FY2023 | $329.4M | +10.0% |
| FY2022 | $299.3M | +43.1% |
| FY2021 | $209.1M | +66.8% |
| FY2020 | $125.4M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice